[{"id":"cd953313-4922-4eb7-86f4-86fd680fb3b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00299728","created_at":"2021-01-18T01:01:31.071Z","updated_at":"2024-07-02T16:36:02.802Z","phase":"Phase 1","brief_title":"NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors","source_id_and_acronym":"NCT00299728","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":" | ","alterations":" CTAG1B expression • CTAG2 expression","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/21/2006","start_date":" 03/21/2006","primary_txt":" Primary completion: 10/10/2006","primary_completion_date":" 10/10/2006","study_txt":" Completion: 01/10/2014","study_completion_date":" 01/10/2014","last_update_posted":"2022-10-10"},{"id":"8ea82e4e-0bda-4bce-8a02-900c33e4f243","acronym":"","url":"https://clinicaltrials.gov/study/NCT02588612","created_at":"2021-01-18T12:33:38.648Z","updated_at":"2024-07-02T16:36:24.831Z","phase":"Phase 1","brief_title":"Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT02588612","lead_sponsor":"GlaxoSmithKline","biomarkers":" EGFR • ALK • ROS1 • HLA-A • CTAG2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • HLA-A*02 • CTAG2 expression","tags":["EGFR • ALK • ROS1 • HLA-A • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • HLA-A*02 • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 08/10/2020","primary_completion_date":" 08/10/2020","study_txt":" Completion: 08/10/2020","study_completion_date":" 08/10/2020","last_update_posted":"2021-09-05"},{"id":"837e1307-aff9-47a1-8cb7-f58eedd670f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03697824","created_at":"2021-01-18T18:07:24.635Z","updated_at":"2025-02-25T16:08:27.486Z","phase":"Phase 1b/2a","brief_title":"Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a","source_id_and_acronym":"NCT03697824","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B • CTAG2","pipe":" | ","alterations":" HLA-A*02 • CTAG2 expression","tags":["HLA-A • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/25/2019","start_date":" 02/25/2019","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 07/18/2022","study_completion_date":" 07/18/2022","last_update_posted":"2019-10-29"}]